Tonix Pharmaceuticals Holding Corp. TNXP
Set alert
As of Nov 2, 10:54 AM ET
- YTD
- -67.38%
- 1 year
- -72.64%
- Open
- 5.10
- Prev close
- 5.10
- Mkt cap
- 87.38M
- Vol
- 103.57K
- Avg vol
- 655.14K
- EPS
- -13.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.04
- High
- 5.22
- Forward P/E
- -0.01
- Beta
- 2.08
- Short ratio
- 0.35
- Inst. own
- 0.23%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.20
- 200-d avg
- 2.41
- 1y target
- 5.83
5D chart
Signals (81)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 9:45 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 9:45 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 9:35 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 9:35 AM | 1 hour ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:10 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:20 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:15 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:50 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 5 days ago |
| RSI: Oversold | Oct 28, 10:05 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:00 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 6 days ago |
News
3 hours ago globenewswire.com
Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation
BERKELEY HEIGHTS, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical…
-
6 days ago benzinga.com
Tonix Pharma Presents Data From Analysis Of Phase 3 RELIEF And RESILIENT Studies Of TONMYA For Treatment Of Fibromyalgia In Adults, At IASP 2026 World Congress
TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studiesTonix…
6 days ago globenewswire.com
Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain
TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studies Tonix…
-
1 week ago benzinga.com
Canaccord Genuity Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $18
Canaccord Genuity analyst Gary Nachman initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $18.
1 week ago globenewswire.com
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company,…
1 week ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
-
2 weeks ago benzinga.com
Tonix Pharmaceuticals To Present Effects Of TONMYA On Fibromyalgia Symptoms And Physical Function At The World Congress On Pain, October 26-30
TONMYA was approved by the U.S. Food and Drug Administration on August 15, 2025, and commercially launched in the U.S. on November 17, 2025.Poster Presentation DetailsTitle: Cyclobenzaprine HCl…
-
1 month ago benzinga.com
Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic TONMYA On Oct 1; Paragraph IV Certification Challenges Four TONMYA Patents Listed In FDA Orange Book; Co Intends To Enforce TONMYA Intellectual Property Rights
On October 1, 2026, Tonix Pharmaceuticals Holding Corp. (the "Company") received a notice (the "Notice") from Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively,
-
1 month ago benzinga.com
Tonix Pharmaceuticals Announces Second Major Managed Medicare Agreement For TONMYA
Agreement for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.).…
-
2 months ago benzinga.com
Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.64) by 7.58 percent. This is a 36.79 percent increase over losses…
-
3 months ago benzinga.com
Tonix Pharma Receives Official Minutes From Type C Meeting With FDA To Discuss Plans For Adaptive Phase 2 Field Study Of TNX-4800 To Prevent Lyme Disease In Adults In US
Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027Long-acting monoclonal antibody TNX-4800 is a rapidly acting alternative…
-
3 months ago benzinga.com
Tonix Pharma Announces Publication Of Monkeypox Study In Journal Of Virology, Peer-Reviewed Publication Of ASM
Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreakThree new models for investigating mpox infection and pathogenesis identifiedTonix is…
-
3 months ago benzinga.com
Tonix Secures Medicare Coverage For Fibromyalgia Drug TONMYA, Expands TONMYA Coverage To 145M Lives By 2027
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or "the Company"), a fully integrated, commercial-stage biotechnology company, today announced a major managed Medicare agreement for TONMYA®
4 months ago benzinga.com
This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades & initiations on analyst ratings page.
4 months ago benzinga.com
This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday
Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratings page for complete view.
4 months ago benzinga.com
This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP stock may be worth considering, analysts say.
-
4 months ago benzinga.com
Raymond James Initiates Coverage On Tonix Pharmaceuticals with Strong Buy Rating, Announces Price Target of $26
Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Strong Buy rating and announces Price Target of $26.
4 months ago benzinga.com
Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA
Tonix Pharmaceuticals Holding shares are trading higher Monday after securing second commercial payer agreement for fibromyalgia drug TONMYA.
-
4 months ago benzinga.com
Tonix Pharmaceuticals Enters Agreement With A Group Purchasing Organization To Provide Coverage For TONMYA To An Additional ~17M U.S. Commercial Lives From June 1
Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million…
-
5 months ago benzinga.com
Tonix Pharma Presents Data From Real-World Claims Analysis Of Opioid Use In US Adults With Fibromyalgia At 2026 ASCP Annual Meeting
Real-world analysis of three years of closed claims data from Symphony Health, focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgiaData…
-
5 months ago benzinga.com
Tonix Pharmaceuticals' TNX-1500 Shows Favorable Safety Profile In Phase 1 Study As Phase 2 Kidney Transplant Trial Set For 2nd Half 2026
Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejectionPhase 2…
-
5 months ago benzinga.com
Tonix Pharmaceuticals' ISPOR 2026 Data Show 93.2% Comorbidity Burden And $29,896 Annual Inpatient Costs Among Fibromyalgia Patients
Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgiaData…
-
5 months ago benzinga.com
Tonix Pharmaceuticals Q1 EPS $(2.93) Misses $(2.43) Estimate, Sales $6.878M Beat $6.100M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.43) by 20.58 percent. This is a 3.17 percent decrease over losses…
6 months ago benzinga.com
Why Tonix Pharmaceuticals Shares Are Rallying Wednesday
Tonix Pharmaceuticals Holding shares are trading higher Wednesday after announcing commercial payer coverage for fibromyalgia drug TONMYA.
-
6 months ago benzinga.com
Tonix Pharmaceuticals Announced An Agreement Effective May 1, 2026, With Group Purchasing Organization For Tonmya (Cyclobenzaprine HCL Sublingual Tablets)
Agreement with leading group purchasing organization (GPO) provides access to approximately 35 million U.S. commercial lives (20% of ~177 million commercial lives in the U.S.)TONMYA (cyclobenzaprine…
-
6 months ago benzinga.com
TD Cowen Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $22
TD Cowen analyst Stacy Ku initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $22.
-
6 months ago benzinga.com
Tonix Pharma Presents Phase 1 Data And Plans For Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease In US At 4th Annual Ticks And Tickborne Diseases Symposium
Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA agreementPhase 2 field study expected to test a…
-
6 months ago benzinga.com
Tonix Pharma Announces Oral Presentation And Two Poster Presentations On Preclinical Immuno-Oncology Portfolio At AACR Annual Meeting 2026
TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical modelsTNX-1700…
-
6 months ago benzinga.com
Tonix Pharmaceuticals Announces Publication Of The Paper "Steady-State Pharmacokinetic Properties Of TNX-102 SL, A Sublingual Tablet Formulation Of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing In Healthy Volunteers: A Randomized, Open-label Trial," In The Journal 'Clinical Pharmacology In Drug Development'
The publication reports findings from a single-center, randomized, open-label, multiple-dose, parallel-group pharmacokinetic study conducted in 60 healthy adult volunteers. Participants were…
-
7 months ago benzinga.com
Tonix Pharmaceuticals Says Phase 1 Data of TNX-4800 (mAb 2217LS) For Preventing Lyme Disease Demonstrated Safety, Tolerability, And Pharmacokinetics Supportive Of Approximately Four Months Protection
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, announced Phase 1 data of TNX-4800 (formerly known as mAb…
7 months ago benzinga.com
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a fresh 52-week low as investors weigh a new SEC filing alongside a biotech pipeline update from…
-
7 months ago benzinga.com
Tonix Announces First Participant Dosed In Phase 1 Investigator-Initiated Study To Evaluate Effect Of TNX-1900 On Trigeminal Nerve-Mediated Vasodilation Of Forehead Using Capsaicin As Well As Electrical Stimulation
Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and…
-
7 months ago benzinga.com
Tonix Pharmaceuticals Presents Phase 1 Data On TNX-4800, Long-Acting Human mAb Targeting OspA Of Borrelia Burgdorferi At World Vaccine Congress Washington 2026
Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease Wednesday, April 1: Animal and in vitro studies on…
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
7 months ago benzinga.com
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch
Tonix Pharmaceuticals beats expectations, and Tonmya prescriptions grow, with over 4,200 prescriptions since launch.
-
7 months ago benzinga.com
Tonix Pharma Announces Two Oral Presentations On TONMYATM, Investigated As TNX-102 SL, At 8th International Congress On Controversies In Fibromyalgia
Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2…
-
7 months ago benzinga.com
Tonix Pharmaceuticals Revealed Data On TONMYATM At The 2026 American Academy of Pain Medicine PainConnect Annual Meeting, in Salt Lake City, Utah; Treatment With TONMYA Provided Statistically Significant Pain Reduction In Two Phase 3 Trials And Was Generally Well Tolerated
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, presented data on TONMYATM (cyclobenzaprine HCl sublingual…
-
8 months ago benzinga.com
Tonix Pharmaceuticals Announces Publication Of Clinical Studies Of TONMYA In Medical Journal
TONMYA™ was investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets) and approved by the U.S. Food and Drug Administration (FDA) on August 15, 2025, for the treatment of fibromyalgia in…
8 months ago benzinga.com
Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting
Tonix shares fell 2% premarket after the Nasdaq Global Select uplisting, with technical indicators signaling short-term weakness.
-
9 months ago benzinga.com
Tonix Pharmaceuticals Presents Data On TONMYA, Which Was Investigated As TNX-102 SL, At 2026 Non-Opioid Pain Therapeutics Summit
TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyUnique sublingual formulation designed for bedtime dosing bypasses first-pass…
10 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session
10 Health Care Stocks With Whale Alerts In Today's Session
10 months ago benzinga.com
Tonix Unveils Once-Yearly Lyme Prevention Antibody, Eyes FDA Talks In 2026
TNXP announced updates on TNX-4800, a long-acting mAb targeting Lyme disease. Seeking FDA meeting in 2026.
-
10 months ago benzinga.com
Tonix Sells 615,025 Shares at $16.26 Each in $20M Stock Deal With Point72
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial stage biotechnology company, today announced it has entered into a securities purchase…
-
10 months ago benzinga.com
Tonix Pharmaceuticals Announces Plans To Meet FDA In 2026 To Mull TNX-4800 Phase 2/3 Development Options
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial stage biotechnology company, today announced program updates on TNX-4800 (formerly known as…
-
10 months ago benzinga.com
Tonix Pharma Announces Licensing Exclusive Worldwide Rights To TNX-4900, Small-Molecule S1R Antagonist With Demonstrated Analgesic Activity In Multiple Models Of Neuropathic Pain
Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic painCompelling safety and pharmacokinetic profiles in animals support…
-
11 months ago benzinga.com
Tonix Pharma Announces FDA Clears IND Application To Support Clinical Development Of TNX-102 SL 5.6 Mg For Treatment Of Major Depressive Disorder In Adults
Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026More than 21 million US adults experience a major depressive episode…
11 months ago benzinga.com
Why Tonix Pharmaceuticals (TNXP) Stock Jumped Monday Morning
Tonix Pharmaceuticals shares are rising Monday morning after the company announced the U.S. commercial availability of its new drug, TONMYA.
-
11 months ago benzinga.com
Tonix Pharmaceuticals' TONMYATM Now Commercially Available Across U.S.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, announced today that TONMYATM (cyclobenzaprine HCl sublingual…
-
11 months ago benzinga.com
Tonix Pharmaceuticals Q3 EPS $(3.59) Misses $(3.58) Estimate, Sales $3.290M Beat $3.100M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(3.59) per share which missed the analyst consensus estimate of $(3.58) by 0.14 percent. This is a 84.17 percent increase over losses…
-
12 months ago benzinga.com
Tonix Teams Up With Mass General To Test New Antibody For Kidney Transplant Patients
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial biotechnology company, today announced a collaboration with Massachusetts General Hospital…